The funds are expected to develop and commercialize the company’s minimally invasive diagnostic and therapeutic products in the U.S. and abroad, according to a Feb. 15 news release. Companion Spine’s devices focus on two applications: degenerative disc disease and lumbar spine stenosis.
Companion Spine’s Diam implant for degenerative disc disease and Aperius implant for the percutaneous treatment of lumbar stenosis are expected to be commercialized in the U.S.
Funding was led by New York City-based investment firm Viscogliosi Brothers.
